AAM
BMRN icon

Archipel Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Archipel Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-138,391
Closed -$9.99M – 68
2013
Q3 		$9.99M Buy
+138,391
New +$9.2M 2.05% 30

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Archipel Asset Management's BMRN Position: Q4 2013 in Review

Archipel Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2013, closing a stake of 138,391 shares — an estimated $9.99M sold.

Archipel Asset Management first reported a position in BMRN in Q3 2013 and held it in 1 quarter. The position peaked at $9.99M in Q3 2013. 307 funds tracked by Wall St. Rank hold BMRN as of Q4 2013.

  • Archipel Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Archipel Asset Management sold 138,391 BioMarin Pharmaceuticals shares in Q4 2013, an estimated $9.99M.
  • Archipel Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Archipel Asset Management's BioMarin Pharmaceuticals position peaked at $9.99M in Q3 2013.
  • 307 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2013.

Based on Archipel Asset Management's 13F filing for Q4 2013, filed 6 Feb 2014.